Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.

Late infantile neuronal ceroid lipofuscinosis (LINCL) is a progressive neurodegenerative lysosomal storage disorder caused by mutations in TPP1, the gene encoding the lysosomal protease tripeptidyl-peptidase (TPP1). LINCL primarily affects children, is fatal and there is no effective treatment. Administration of recombinant protein has proved effective in treatment of visceral manifestations of other lysosomal storage disorders but to date, only marginal improvement in survival has been obtained for neurological diseases. In this study, we have developed and optimized a large-volume intrathecal administration strategy to deliver therapeutic amounts of TPP1 to the central nervous system (CNS) of a mouse model of LINCL. To determine the efficacy of treatment, we have monitored survival as the primary endpoint and demonstrate that an acute treatment regimen (three consecutive daily doses started at 4 weeks of age) increases median lifespan of the LINCL mice from 16 (vehicle treated) to 23 weeks (enzyme treated). Consistent with the increase in life-span, we also observed significant reversal of pathology and improvement in neurological phenotype. These results provide a strong basis for both clinical investigation of large-volume/high-dose delivery of TPP1 to the brain via the cerebrospinal fluid (CSF) and extension of this approach towards other neurological lysosomal storage diseases.

[1]  B. Byrne,et al.  Recombinant human acid α-glucosidase , 2007, Neurology.

[2]  I. Verma,et al.  Targeted delivery of proteins across the blood–brain barrier , 2007, Proceedings of the National Academy of Sciences.

[3]  M. Porteus,et al.  A Look to Future Directions in Gene Therapy Research for Monogenic Diseases , 2006, PLoS genetics.

[4]  W. Mobley,et al.  Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. , 2004, Molecular genetics and metabolism.

[5]  W. Pardridge,et al.  Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[6]  D. Peterson,et al.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Corinne R. Fantz,et al.  AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  D. Peterson,et al.  Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis , 2008, Experimental Neurology.

[9]  R. Sidman,et al.  A Mouse Model of Classical Late-Infantile Neuronal Ceroid Lipofuscinosis Based on Targeted Disruption of the CLN2 Gene Results in a Loss of Tripeptidyl-Peptidase I Activity and Progressive Neurodegeneration , 2004, The Journal of Neuroscience.

[10]  P. Lobel,et al.  Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays. , 2000, Clinical chemistry.

[11]  B. Davidson,et al.  Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  B. Karolewski,et al.  Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Xiao-jun Xu,et al.  Chronic lumbar catheterization of the spinal subarachnoid space in mice , 2004, Journal of Neuroscience Methods.

[14]  P. Dickson.  Novel treatments and future perspectives: outcomes of intrathecal drug delivery. , 2009, International journal of clinical pharmacology and therapeutics.

[15]  M. Jadot,et al.  Glial fibrillary acidic protein is elevated in the lysosomal storage disease classical late-infantile neuronal ceroid lipofuscinosis, but is not a component of the storage material. , 2010, The Biochemical journal.

[16]  A. Golabek,et al.  A Critical Tryptophan and Ca2+ in Activation and Catalysis of TPPI, the Enzyme Deficient in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis , 2010, PloS one.

[17]  M. Mcentee,et al.  Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. , 2007, Molecular genetics and metabolism.

[18]  S. McCandless,et al.  A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). , 2007, Molecular genetics and metabolism.

[19]  J. Hopwood,et al.  Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. , 2007, Molecular genetics and metabolism.

[20]  F. Tison,et al.  A simple method to measure stride length as an index of nigrostriatal dysfunction in mice , 2002, Journal of Neuroscience Methods.

[21]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[22]  S. Walkley,et al.  Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. , 2008, Molecular genetics and metabolism.

[23]  M. Souweidane,et al.  Neurological deterioration in late infantile neuronal ceroid lipofuscinosis , 2007, Neurology.

[24]  M. Sands,et al.  Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases , 2009, Experimental Neurology.

[25]  W. Sly,et al.  Chemically modified β-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII , 2008, Proceedings of the National Academy of Sciences.

[26]  D. Tsuji,et al.  Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis , 2011, Annals of neurology.

[27]  D. Dickson,et al.  Single‐dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  Sunghuen Kim,et al.  A Report of Two Cases , 2008 .

[29]  T. Lerner,et al.  Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. , 1999, American journal of human genetics.

[30]  R. Crystal,et al.  Intracranial Delivery of CLN2 Reduces Brain Pathology in a Mouse Model of Classical Late Infantile Neuronal Ceroid Lipofuscinosis , 2006, The Journal of Neuroscience.

[31]  H. Goebel,et al.  Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. , 2002, American journal of medical genetics.

[32]  J. Hopwood,et al.  Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. , 2009, International journal of clinical pharmacology and therapeutics.

[33]  K. Kovács,et al.  Chronic daily intrathecal injections of a large volume of fluid increase mast cells in the thalamus of mice , 2005, Brain Research.

[34]  A. Boer,et al.  Strategies to Improve Drug Delivery Across the Blood-Brain Barrier , 2007, Clinical pharmacokinetics.

[35]  M. Warburton,et al.  Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I 1 , 1999, FEBS letters.

[36]  M. Passini,et al.  AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  C. Vite,et al.  Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. , 2011, Molecular genetics and metabolism.

[38]  B. Davidson,et al.  Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  D. Dickson,et al.  Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  W. Sly,et al.  Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Ryazantsev,et al.  Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B. , 2007, Molecular genetics and metabolism.

[42]  R. Brady.  Enzyme replacement for lysosomal diseases. , 2006, Annual review of medicine.

[43]  J. Walker,et al.  Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). , 1992, American journal of medical genetics.

[44]  P. Lobel,et al.  Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. , 2001, The Biochemical journal.

[45]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.

[46]  A. Kreuger,et al.  Cerebrospinal fluid exchange after intrathecal methotrexate overdose. A report of two cases , 1992, Acta paediatrica.

[47]  Thomas Brinker,et al.  Multiplicity of cerebrospinal fluid functions: New challenges in health and disease , 2008, Cerebrospinal Fluid Research.

[48]  R. Donnelly,et al.  Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. , 1997, Science.